In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Plethora may get $28mm through arrangement with Paul Capital

Executive Summary

Plethora Solutions Holdings PLC (urological conditions) has signed an agreement with Paul Capital Healthcare under which Plethora gets up to $28mm--$15mm cash up front, $10mm cash upon the first US sale of PSD502, and $3mm in equity--in exchange for revenue interest in Plethora's male health portfolio. The interest will mainly come from ErecAid (sold by the company's Timm Medical subsidiary for erectile dysfunction), PSD502 (Phase III for premature ejaculation and erectile dysfunction), and PSD510 (Phase III for erectile dysfunction).
Deal Industry
  • Biotechnology
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies

Advertisement
UsernamePublicRestriction

Register